Zinforo 600 mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 12 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of ABSSSI and CABP caused by susceptible bacteria.
Dosage (summary)
600 mg IV every 12 hours; high dose 600 mg every 8 hours for specific infections.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Low interaction potential with CYP450 drugs
Contraindications
- Hypersensitivity to ceftaroline or beta-lactams
Common side effects
- Diarrhoea
- Headache
- Nausea
- Pruritus
Counselling Points
- Report any allergic reactions
- Monitor for diarrhoea during treatment
Serious warnings
- Serious hypersensitivity reactions
- Clostridium difficile-associated diarrhoea
Important Disclaimer
The Zinforo 600 mg Powder for concentrate for solution for infusion professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
